SURMOUNT-OSA Study Highlights Potential
Dual-Action Benefits of Novel Therapy for Obesity
ORLANDO,
Fla., June 21, 2024 /PRNewswire/ -- Today,
findings from the SURMOUNT-OSA, a study of tirzepatide in patients
with obstructive sleep apnea (OSA) and obesity, were announced,
revealing significant improvements in both sleep apnea severity and
related metabolic issues. The results were presented as a
Late-Breaking Symposium at the 84th Scientific Sessions of the
American Diabetes Association® (ADA) in Orlando, FL, and were simultaneously published
in the New England Journal of Medicine (NEJM).
OSA affects up to 1 billion people globally and over 30 million
adults in America alone. It is particularly common in individuals
with obesity, which is the most significant risk factor. About 40%
of people with obesity have OSA, and around 70% of OSA patients
have obesity. This condition, marked by repeated airway obstruction
during sleep, leads to various health issues, including
hypertension, cardiovascular disease, diabetes, stroke, and
impaired cognitive function. Traditional treatments for OSA, like
continuous positive airway pressure (CPAP) devices, do not address
obesity revealing a need for solutions that can treat both sleep
apnea and obesity. The SURMOUNT-OSA study investigates tirzepatide,
a novel treatment targeting both conditions.
The two randomized, double-blind, placebo-controlled trials
included 469 individuals with moderate-to-severe OSA and obesity.
Study 1 enrolled patients unable or unwilling to use PAP therapy
and Study 2 enrolled patients on PAP therapy at baseline.
Participants were assigned to receive either tirzepatide or a
placebo for 52 weeks. The primary endpoint was the change in the
apnea-hypopnea index (AHI), which measures the severity of sleep
apnea. Key secondary endpoints included change of sleep apnea
specific hypoxic burden (SASHB), CV risk factors including changes
in body weight, systolic blood pressure and inflammation (hsCRP),
and changes in patient-reported sleep related impairment and sleep
disturbance.
Key findings revealed that participants who took tirzepatide
experienced a significant decrease in AHI compared to those who
took the placebo, indicating an improvement in sleep disordered
breathing. In Study 1, the change in AHI at 52 weeks was -27.4 and
-30.4 events/h with tirzepatide and -4.8 and -6,0 events/h with
placebo in Study 1 and Study 2, respectively. Notable changes of CV
risk factors included reductions in body weight (18% in Study 1,
and 20% in Study 2) and improvements in systolic blood pressure
(-9.6 in Study 1 and -7.6 in Study 2).
"The results of the study have demonstrated the ability of
tirzepatide to address both obesity and sleep apnea, offering an
effective and comprehensive treatment solution," said Atul Malhotra, MD, professor of medicine at
University of California San Diego
School of Medicine, director of sleep medicine at UC San Diego
Health, and the study's principal investigator and lead author of
the NEJM article. "Its potential to be used alongside or
independently of CPAP could revolutionize how we manage these
interconnected conditions. These findings show the potential for
the first highly effective drug treatment for sleep apnea."
Looking ahead, the authors emphasized the need for further
analyses to explore the long-term benefits of tirzepatide on
cardiovascular outcomes and its potential role in the broader
management of obesity-related conditions.
Research presentation details:
Dr. Malhotra will present the findings at the following
symposium:
- Late-Breaking Symposium: SURMOUNT-OSA Trial Results and
Potential Role of Tirzepatide in Treating Obesity-Related
Obstructive Sleep Apnea
- Presented on Friday, June 21,
2024 at 3:45 PM ET.
About the ADA's Scientific Sessions
The ADA's 84th Scientific Sessions, the world's largest
scientific meeting focused on diabetes research, prevention, and
care, will be held in Orlando, FL
on June 21-24. More than 11,000
leading physicians, scientists, and health care professionals from
around the world are expected to convene both in person and
virtually to unveil cutting-edge research, treatment
recommendations, and advances toward a cure for diabetes. Attendees
will receive exclusive access to thousands of original research
presentations and take part in provocative and engaging exchanges
with leading diabetes experts. Join the Scientific Sessions
conversation on social media using
#ADAScientificSessions.
About the American Diabetes Association
The American Diabetes Association (ADA) is the nation's leading
voluntary health organization fighting to bend the curve on the
diabetes epidemic and help people living with diabetes thrive. For
83 years, the ADA has driven discovery and research to treat,
manage, and prevent diabetes while working relentlessly for a cure.
Through advocacy, program development, and education we aim to
improve the quality of life for the over 136 million Americans
living with diabetes or prediabetes. Diabetes has brought us
together. What we do next will make us Connected for Life®. To
learn more or to get involved, visit us
at diabetes.org or call 1-800-DIABETES (1-800-342-2383).
Join the fight with us on Facebook (American Diabetes Association),
Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn
(American Diabetes Association), Twitter (@AmDiabetesAssn), and
Instagram (@AmDiabetesAssn).
Contact:
Amy Robinson
arobinson@brgcommunications.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/use-of-tirzepatide-shown-to-improve-sleep-apnea-and-cardiovascular-outcomes-302178776.html
SOURCE American Diabetes Association